Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 287–288.

https://doi.org/10.1182/blood-2022-159357

Published: 2022

Journal Articles

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Blood (2012) 120 (21): 2012.

https://doi.org/10.1182/blood.V120.21.2012.2012

Published: 2012

Journal Articles

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Nicolaus Kröger, Tatjana Zabelina, MD, Francis Ayuk, MD, Christine Wolschke, MD, Haefaa Alchalby, Anita Badbaran, Djordje Atanackovic, M.D., Georgia Schilling, MD, Orhan Sezer, MD, PhD, Ulrike Bacher, MD, Thomas Stübig, MD, Boris Fehse, Ph.D., Axel R. Zander, MD

Blood (2011) 118 (21): 148.

https://doi.org/10.1182/blood.V118.21.148.148

Published: 2011

Journal Articles

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Nicolaus Kröger, Evgeny Klyuchnikov, MD, Thomas Stübig, MD, Christine Wolschke, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, York Hildebrandt, Ulrike Bacher, MD, Anita Badbaran, Georgia Schilling, MD, Orhan Sezer, MD, PhD, Djordje Atanackovic, M.D., Martin Kropff, MD, Axel R. Zander, MD

Blood (2011) 118 (21): 3024.

https://doi.org/10.1182/blood.V118.21.3024.3024

Published: 2011

Journal Articles

Cig-FISH-Analysis of Extramedullary Myeloma Manifestations Shows Similar Incidence of Prognostic Genetic Aberrations Compared to Bone Manifestations or Soft Tissue Involvement

Lisa Billecke, PhD, Eva Maria Murga Penas, PhD, Annette May, PhD, Monika Engelhardt, Arnon Nagler, M.D., Merav Leiba, PhD, Nicolaus Kröger, PhD, Jozef Zustin, PhD, Andreas Marx, PhD, Jakob Matschke, Markus Tiemann, MD, Eray Gökkurt, Carsten Bokemeyer, MD, Georgia Schilling, PhD

Blood (2010) 116 (21): 4993.

https://doi.org/10.1182/blood.V116.21.4993.4993

Published: 2010

Journal Articles

Chromosomes 2q, 4q and 13q21 Are Preferential Targets of Epstein-Barr Virus (EBV) Integration In Burkitt's Lymphoma Cell Lines

Eva Maria Murga Penas, PhD, Juliane Hinke, Petra Behrmann, Snjezana Janjetovic, MD, Georgia Schilling, MD, Carsten Bokemeyer, MD, Judith Dierlamm, MD, PhD

Blood (2010) 116 (21): 4452.

https://doi.org/10.1182/blood.V116.21.4452.4452

Published: 2010

Journal Articles

Incidence of ETV6 Cryptic Translocations In Myeloid Disorders

Eva Maria Murga Penas, PhD, Marianne Klokow, Petra Behrmann, Snjezana Janjetovic, MD, Georgia Schilling, MD, Carsten Bokemeyer, MD, Judith Dierlamm, MD, PhD

Blood (2010) 116 (21): 2733.

https://doi.org/10.1182/blood.V116.21.2733.2733

Published: 2010

Journal Articles

The t(14;18)(q32;q21)/ IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma

Eva Maria Murga Penas, Evelyne Callet-Bauchu, Hongtao Ye, Sophie Gazzo, Françoise Berger, Georgia Schilling, Nadine Albert-Konetzny, Eik Vettorazzi, Gilles Salles, Iwona Wlodarska, Ming-Qing Du, Carsten Bokemeyer, Judith Dierlamm

Blood (2010) 115 (11): 2214–2219.

https://doi.org/10.1182/blood-2009-08-236265

Published: 2010

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.

Avichai Shimoni, Izhar Hardan, Francis Ayuk, Georgia Schilling, Djordje Atanackovic, Wolfgang Zeller, Noga Shem-Tov, Avital Rand, Ronit Yerushalmi, Axel Zander, Nicolaus Kroger, Arnon Nagler

Blood (2009) 114 (22): 3359.

https://doi.org/10.1182/blood.V114.22.3359.3359

Published: 2009

Journal Articles

Unrelated Stem Cell Transplantation After Reduced Intensity Conditioning for Patients with Multiple Myeloma Relapsing After Autologous Transplantation A Prospective Multicenter Phase II Study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Nicolaus Kröger, MD, Avichai Shimoni, Georgia Schilling, Rainer Schwerdtfeger, MD, Martin Bornhäuser, Arnon Nagler, Axel R. Zander, Marion Heinzelmann, Ronald Brand, Goesta Gahrton, MD, PhD, Currly Morris, Dietger Niederwieser, T. M. de Witte

Blood (2009) 114 (22): 2308.

https://doi.org/10.1182/blood.V114.22.2308.2308

Published: 2009

Journal Articles

Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.

Nicolaus Kröger, MD, Tatjana Zabelina, Marion Heinzelmann, Georgia Schilling, Christine Wolschke, Heinrich Lellek, Thomas Stübig, Maite Lestin, Haefaa Alchalby, Francis Ayuk, Djordje Atanackovic, M.D., Ulrike Bacher, Boris Fehse, Axel R. Zander

Blood (2009) 114 (22): 1201.

https://doi.org/10.1182/blood.V114.22.1201.1201

Published: 2009

Journal Articles

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Blood (2008) 112 (11): 2776.

https://doi.org/10.1182/blood.V112.11.2776.2776

Published: 2008

Journal Articles

Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, Avichai Shimoni, Jose-Antonio Simon-Perez, Wolfgang Bethge, Peter Liebisch, Rainer Schwerdtfeger, Martin Bornhaeuser, Svenja Otterstetter, Francis Ayuk, Carsten Bokemeyer, Axel R. Zander, Jesus San-Miguel, Arnon Nagler, Nicolaus Kroeger

Blood (2007) 110 (11): 4743.

https://doi.org/10.1182/blood.V110.11.4743.4743

Published: 2007

Journal Articles

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, MD, Peter Liebisch, MD, Rainer Schwerdtfeger, PD, Jose Antonio Perez-Simon, MD, Martin Bornhaeuser, PD, Svenja Otterstetter, Judith Dierlamm, PD, Arnon Nagler, Dieter Kurt Hossfeld, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kroeger, PD

Blood (2006) 108 (11): 5038.

https://doi.org/10.1182/blood.V108.11.5038.5038

Published: 2006

Journal Articles

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation

Djordje Atanackovic, Julia Arfsten, Yanran Cao, Sacha Gnjatic, Frank Schnieders, Katrin Bartels, Georgia Schilling, Christiane Faltz, Christine Wolschke, Judith Dierlamm, Gerd Ritter, Thomas Eiermann, Dieter Kurt Hossfeld, Axel R. Zander, Achim A. Jungbluth, Lloyd J. Old, Carsten Bokemeyer, Nicolaus Kröger

Blood (2006) 109 (3): 1103–1112.

https://doi.org/10.1182/blood-2006-04-014480

Published: 2006

Includes: Supplemental data

Journal Articles

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Georgia Schilling, MD, Timon Hansen, Jose Antonio Perez-Simon, MD, Rainer Schwerdtfeger, MD, Martin Bornhaeuser, MD, Svenja Otterstetter, Doris Seeger, Judith Dierlamm, PD, Francis Ayuk, MD, Hossfeld Dieter Kurt, Bokemeyer Carsten, Zander R. Axel, Kroeger Nicolaus, PD

Blood (2005) 106 (11): 4338.

https://doi.org/10.1182/blood.V106.11.4338.4338

Published: 2005

Journal Articles

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Nicolaus Kröger, Georgia Schilling, Hermann Einsele, Peter Liebisch, Avichai Shimoni, Arnon Nagler, Jose A. Perez-Simon, Jesus F. San Miguel, Michael Kiehl, Axel Fauser, Rainer Schwerdtfeger, Hannes Wandt, Herbert G. Sayer, Han Myint, Hans Klingemann, Tatjana Zabelina, Judith Dierlamm, Axel Hinke, Axel R. Zander

Blood (2004) 103 (11): 4056–4061.

https://doi.org/10.1182/blood-2003-12-4435

Published: 2004

NARROW

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Cig-FISH-Analysis of Extramedullary Myeloma Manifestations Shows Similar Incidence of Prognostic Genetic Aberrations Compared to Bone Manifestations or Soft Tissue Involvement

Chromosomes 2q, 4q and 13q21 Are Preferential Targets of Epstein-Barr Virus (EBV) Integration In Burkitt's Lymphoma Cell Lines

Incidence of ETV6 Cryptic Translocations In Myeloid Disorders

The t(14;18)(q32;q21)/ IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.

Unrelated Stem Cell Transplantation After Reduced Intensity Conditioning for Patients with Multiple Myeloma Relapsing After Autologous Transplantation A Prospective Multicenter Phase II Study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only